Valeo Enters Commercialization and Supply Agreement With Novartis To Address the $700M/ Year Canadian Asthma Medication Market

Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) announced today that it has entered into a Commercialization and Supply Agreement with Novartis Pharmaceuticals Canada Inc.for the Canadian commercialization by Valeo of two asthma therapies, Enerzair ® Breezhaler ® (indacaterol (as acetate),  glycopyrronium (as bromide) and mometasone furoate) 3 and Atectura ® Breezhaler ® (indacaterol (as acetate) and mometasone furoate).  Under the Agreement, Valeo will be responsible for medical and commercial activities for an initial 8 year period. How Significant Is This Market? At present, almost 4 million Canadians are living with asthma a serious health issue affecting all age groups. Patients with severe asthma live in fear of potential exacerbations which remain highly prevalent even with today's most advanced therapies. The Canadian market for asthma medication exceeds $700M annually. What Does The CEO of Valeo say about the deal? "We are extremely pleased to be partnering with Novartis to launch these two  asthma drugs in the coming weeks. Commercializing Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® will immediately position Valeo as one of the leading Canadian respiratory companies providing first in-class and best in-class asthma therapies. The Canadian asthma maintenance market exceeds $700M annually," said Steve Saviuk , CEO of Valeo. "This partnership is perfectly aligned with Valeo's vision and mission of building a Canadian anchor pharmaceutical company by driving therapeutic innovation to patients in need. We look forward to building a long and mutually beneficial relationship with Novartis that will help both companies fulfill their respective missions." Sit Back, relax and watch this powerful interview with Steve Saviuk , CEO of Valeo.